Chromosome 5q Deletion - 9 Studies Found Terminated : Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome : Myelodysplastic Syndrome (MDS) : 2011-08-18 : Drug: ezatiostat hydrochloride (Telintra®) Three weeks of treatment with ezatiostat at 2000 mg per Completed : Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia : Myelodysplastic Syndrome (MDS) : 2011-04-13 : Drug: Azacitidine Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be a Completed : Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality : Myelodysplastic Syndromes : 2005-09-10 : Drug: Lenalidomide 5 mg Lenali Completed : Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q : Myelodysplastic Syndromes : 2010-03-02 : Drug: Lenalidomide 10 mg d1-d21 of a 28-day cycle Ot Terminated : Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) : Leukemia : 2010-10-14 : Drug: Lenalidomide 10 mg/day b Active, not recruiting : A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q : Anemia : 2009-12-08 : Drug: Lenalidomide One 10 mg L Recruiting : Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome : Myelodysplastic Syndrome : 2010-11-17 : Drug: Lenalidomide Treatment w Completed : MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry : Myelodysplastic Syndrome : 2010-10-29 : Drug: lenalidomide Patients who were prescribed Revlimid from 31October 2008 to present. Completed : A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q : Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia A : 2009-04-21 : Drug: Lenalidomide Inducti
